Freshly Funded ImCheck Goes After Gamma Delta T-Cells

$53m Series B Financing Will Advance ImCheck Therapeutics’ Pipeline

 
• By Sten Stovall

ImCheck’s $53m series B financing will be used to develop antibodies that activate gamma delta T-cells for use against cancer and autoimmune diseases, its CEO tells Scrip.

Immune_System
Gamma delta T-cells have active role in body's early immune response • Source: Shutterstock

More from Immuno-oncology

More from Anticancer